New radioactive drug targets Hard-to-Treat prostate cancer

NCT ID NCT05983198

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check the drug's safety and how well it works in 33 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 225Ac-PSMA-R2 (a radioactive drug that targets prostate cancer cells)
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial with only 33 participants, so results may not apply broadly. The drug is radioactive and may cause side effects like damage to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

BAMF Health

Grand Rapids, Michigan, 49503, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Novartis Investigative Site

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site

Montreal, Quebec, H2X 1R9, Canada
Novartis Investigative Site

Dijon, Cote D Or, 21034, France
Novartis Investigative Site

Clermont-Ferrand, 63011, France
Novartis Investigative Site

Lyon, 69373, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Saint-Herblain, 44805, France
Novartis Investigative Site

Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.